Intent-to-treat vs. non-intent-to-treat analyses under treatment nonadherence in mental health randomized trials. Psychiatric Annals 2008; 38

The intent-to-treat (ITT) principle has long been mandated by the Food and Drug Administration (FDA) as the primary design and analysis strategy for industry clinical trials and also has been adopted widely in government-funded randomized clinical trials (1–4). Intent-to-treat analysis aims to estimate the effect of treatment as offered, or as assigned